[On the Distribution of AR-EcoScreen GR KO M1 (JCRB1761)]
The distribution of AR-EcoScreen GR KO M1 is regulated by the developer of cell line.
Before the distribution of this cell line, users belonging non-profit organization are requested to complete an MTA between the user and the developer. Users belonging to profit-making organization are requested a contract with license fee between the user and developer. Also, please note that even if the user is belonging to non-profit organization, an additional contract is required for the usage of cells for commercial purposes
For the distribution, the developer will request the detail purpose of usage of this cell line.
Please clearly describe the research purposes in the "Request and Agreement Form (Form A)".
[Close]
[JCRB1761 AR-EcoScreen GR KO M1細胞の分譲について]
JCRB1761 AR-EcoScreen GR KO M1細胞の分譲は細胞樹立者(権利者)により制限されています。
分譲に先立ち、非営利学術団体に属する利用者は、細胞樹立者との間でMTAを別途手交していただく必要がございます。
また、営利団体に所属する利用者は、細胞樹立者と間で契約(有償)を締結していただく必要がございます。
本細胞の分譲におきましては、細胞樹立者から詳細な細胞の利用目的を求められます。
バンク規定の分譲依頼書・同意書には、研究目的を必ずご記入ください。いただいた分譲依頼書・同意書は、細胞バンクから細胞樹立者・寄託者にそのコピーを送付します。
[Close]
| JCRB No. |
JCRB1761 |
Cell Name |
AR-EcoScreen GR KO M1 |
| Profile |
AR-EcoScreen is for evaluation of a rapid in vitro androgen receptor tarnscriptional activation assay. Furthermore, this cell line specifically knocked out the glucocorticoid receptor (GR) gene. |
Other Name |
|
| Animal |
hamster, Chinese |
Strain |
Chinese |
| Genus |
Cricetulus |
Species |
griseus |
| Sex |
|
Age |
|
| Identity |
|
Tissue for Primary Cancer |
|
| Case history |
|
Metastasis |
N |
| Tissue Metastasized |
|
Genetics |
This cell is that stably express human androgen receptor, reportor gene (androgen response element linked to luciferase), and firefly luciferase gene. Furthermore, this cell line specifically knocked out the glucocorticoid receptor (GR) gene. |
| Life Span |
infinite |
Crisis PDL |
|
| Morphology |
epithelial-like |
Character |
|
| Classify |
|
Established by |
Nick Zwart |
| Registered by |
Hiroyuki Kojima |
Regulation for Distribution |
MTA between applicant and developer is required. |
| Comment |
|
Year |
|
| Medium |
DMEM/F12 medium supplemented with 10% fetal bovine serum, hygromycin (25ug/mL) and zeocin (50 ug/mL). |
Methods for Passages |
Cells are treated with 0.25% trypsin and 0.02% EDTA. |
| Cell Number on Passage |
split ratio=1/10 |
Race |
|
| CO2 Conc. |
5% |
Tissue Sampling |
ovary |
| Tissue Type |
|
